Christopher Dakhil

560 total citations
20 papers, 393 citations indexed

About

Christopher Dakhil is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Christopher Dakhil has authored 20 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Christopher Dakhil's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Christopher Dakhil is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Christopher Dakhil collaborates with scholars based in United States, Canada and Switzerland. Christopher Dakhil's co-authors include David S. Shames, Sylvia Hu, Vamsidhar Velcheti, Philip J. Stella, Mark A. Socinski, Tarek Mekhail, Ticiana Leal, Erica Schleifman, Edward S. Kim and Cindy Yun and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Dakhil

19 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Dakhil United States	8	263	197	130	56	43	20	393
Paloma Martín-Martorell Spain	11	279 1.1×	190 1.0×	52 0.4×	35 0.6×	82 1.9×	30	426
Benjamin Bonhomme France	8	131 0.5×	81 0.4×	44 0.3×	35 0.6×	45 1.0×	15	261
Alessandra Bologna Italy	12	288 1.1×	74 0.4×	62 0.5×	47 0.8×	118 2.7×	37	421
Christopher DiSimone United States	6	271 1.0×	148 0.8×	85 0.7×	58 1.0×	114 2.7×	10	490
Yalun Li China	12	164 0.6×	163 0.8×	89 0.7×	82 1.5×	117 2.7×	39	412
Samuel Suzuki United States	9	228 0.9×	130 0.7×	102 0.8×	39 0.7×	214 5.0×	22	460
Chi‐Chung Tong China	13	271 1.0×	136 0.7×	105 0.8×	35 0.6×	76 1.8×	31	590
Alessandra Anna Prete Italy	9	388 1.5×	158 0.8×	144 1.1×	95 1.7×	66 1.5×	27	497
Leylah Drusbosky United States	13	223 0.8×	183 0.9×	188 1.4×	44 0.8×	198 4.6×	72	522
Chang Hun Lee South Korea	11	172 0.7×	86 0.4×	74 0.6×	93 1.7×	92 2.1×	29	341

Countries citing papers authored by Christopher Dakhil

Since Specialization

Citations

This map shows the geographic impact of Christopher Dakhil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Dakhil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Dakhil more than expected).

Fields of papers citing papers by Christopher Dakhil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Dakhil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Dakhil. The network helps show where Christopher Dakhil may publish in the future.

Co-authorship network of co-authors of Christopher Dakhil

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Dakhil. A scholar is included among the top collaborators of Christopher Dakhil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Dakhil. Christopher Dakhil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okut, Hayrettin, Shaker R. Dakhil, Christopher Dakhil, et al.. (2024). Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer.. Journal of Clinical Oncology. 42(16_suppl). e12518–e12518.

Kim, Edward S., Vamsidhar Velcheti, Tarek Mekhail, et al.. (2022). Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine. 28(5). 939–945. 111 indexed citations

Choucair, Khalil, Bassam Mattar, Christopher Dakhil, et al.. (2022). Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice. The Oncologist. 27(3). 183–190. 7 indexed citations

Patel, Jyoti D., Ju-Whei Lee, David P. Carbone, et al.. (2020). Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer. 21(6). 520–526. 18 indexed citations

Le‐Rademacher, Jennifer, Kendrith M. Rowland, Philip J. Atherton, et al.. (2019). Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series. American Journal of Hospice and Palliative Medicine®. 36(6). 519–525. 5 indexed citations

Leon‐Ferre, Roberto A., Paul J. Novotny, Eric Wolfe, et al.. (2019). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectrum. 4(1). pkz088–pkz088. 52 indexed citations

Socinski, Mark A., Vamsidhar Velcheti, Tarek Mekhail, et al.. (2019). Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 30. v919–v920. 41 indexed citations

Flora, Daniel, et al.. (2019). Abstract GS6-02: A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603. Cancer Research. 79(4_Supplement). GS6–2. 5 indexed citations

Dakhil, Christopher, et al.. (2019). Metastasis of Benign Leiomyomas Outside the Uterus. Kansas Journal of Medicine. 11(2). 56–58. 7 indexed citations

10.

Patel, Jyoti D., Henry Wagner, D. Carbone, et al.. (2018). MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC. Journal of Thoracic Oncology. 13(10). S370–S370. 1 indexed citations

11.

Langer, Corey J., Edward S. Kim, Eric Anderson, et al.. (2018). nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology. 8. 262–262. 7 indexed citations

12.

Velcheti, Vamsidhar, Tarek Mekhail, Ticiana Leal, et al.. (2018). Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii744–viii744. 47 indexed citations

13.

Velcheti, Vamsidhar, Edward S. Kim, Tarek Mekhail, et al.. (2018). Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.. Journal of Clinical Oncology. 36(15_suppl). 12001–12001. 34 indexed citations

14.

Schnadig, Ian D., Richy Agajanian, Christopher Dakhil, et al.. (2017). APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Management and Research. Volume 9. 179–187. 6 indexed citations

15.

Langer, Corey J., Eric Anderson, Robert M. Jotte, et al.. (2017). ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 9059–9059. 2 indexed citations

16.

Schnadig, Ian D., Richy Agajanian, Christopher Dakhil, et al.. (2016). APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy. Future Oncology. 12(12). 1469–1481. 17 indexed citations

17.

Dakhil, Christopher, et al.. (2015). Undiagnosed Systemic Lupus Erythematosus Presenting as Hemophagocytic Lymphohistiocytosis. SHILAP Revista de lepidopterología. 2015. 1–3. 6 indexed citations

18.

Kasi, Anup, et al.. (2014). Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report. Journal of Medical Case Reports. 8(1). 299–299. 3 indexed citations

19.

Dakhil, Christopher, et al.. (2014). Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. Medical Oncology. 31(10). 187–187. 18 indexed citations

20.

Dakhil, Christopher, et al.. (2013). Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rapidly Progressive and Fatal Disease without Aggressive Intervention. Clinical Medicine Insights Case Reports. 6. 201–4. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact